NCT07655115招募中3 期
A Follow-Up Shiftability Study of Arbaclofen With an Open-Label Extension for the Study of Biomarkers in Children and Adolescents With Autism Spectrum Disorders.
Hospital General Universitario Gregorio Marañon5 个研究点 分布在 2 个国家目标入组 103 人开始时间: 2025年11月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 103
- 试验地点
- 5
- 主要终点
- Change in power in the low frequency bands (theta/alpha) (between visits 1 and 2).
研究概览
简要总结
study with arbaclofen (4 weeks of titration and then 6 weeks of active/stable treatment). The effects of arbaclofen on target EEG and ERG metrics will be associated with the clinical response in measures of social and general function, adaptive behaviour, social anxiety, sensory behaviours, global functioning, and quality of life in Children and Adolescents with Autism Spectrum Disorders
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 0 Years 至 64 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Written Informed Consent a.Participants or their legal representative must have signed and dated an IRB/IEC approved written informed consent form
- •Diagnosis of an Autism Spectrum Disorder according to the DSM-5 criteria
- •Participation in the AIMS-2 CT1 (ages at recruitment 5 to 17).
- •Current pharmacological treatment regimen affecting behaviour has been stable for at least 6 weeks prior to screening and is expected to be stable during the duration of the study
- •Current psychotherapeutic/psychosocial interventions affecting behaviour stable for 3 months prior to screening and expected to be stable during the duration of the study
- •Participants with a history of seizure disorder must currently be receiving stable treatment with anticonvulsant medication and must have been seizure free for 6 months prior to screening or must be seizure free for 3 years prior to screening if not currently on a stable (>3 months) dose of antiepileptics
- •Male or female participants 7 to 23 years of age at the time of providing consent, inclusive.
- •Reside or regular contact (at least twice a week) with the parent/carer who is interviewed for the study.
- •Negative pregnancy test for females of childbearing potential (participant has experienced onset of menses)
- •Females of childbearing potential who are sexually active must agree to use a highly effective form of contraception (i.e., existing surgical sterilization, complete or abstinence or a combination of two affective forms of contraception, such as, for example, condoms plus hormonal treatment). Please, refer to Appendix 4 for a complete list of acceptable contraception methods.(protocol)
- •Male participants with female partners of childbearing potential are eligible to participate if they agree to the conditions stated in section 8.2.1.(protocol)
排除标准
- •Participants with any condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being.
- •Participants who are currently receiving treatment with racemic baclofen, vigabatrin, tiagabine, or riluzole or other GABA-related medications (e.g. gabapentin or pregabalin) other than arbaclofen in the context of AIMS-2 CT1
- •Participants who are currently receiving pharmacologic treatment affecting behaviour (see concomitant medication section) need to have a stable dose during the 6 weeks prior to the screening visit and for the duration of the study.
- •Participating in programs including non-pharmacologic educational, behavioural, and/or dietary interventions affecting behaviour, participation in these programs must have been continuous during the 3 months prior to screening and participants or their parent/caregiver/LAR may not electively initiate new or modify ongoing interventions for the duration of the study. Typical school vacations are not considered modifications of stable programming
- •Participants who have taken another investigational drug within the last 30 days.
- •Participants with evidence of any significant haematological, endocrine, cardiovascular (including uncorrected symptomatic congenital heart disease), respiratory, renal, hepatic, or gastrointestinal disease, not including mild common paediatric diseases in these areas that are stable (e.g. mild asthma, constipation, etc.), as judged by the investigator.
- •Participants who are not able to take oral medications.
- •Participants who have a history of hypersensitivity to racemic baclofen
- •Participants with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption should not take this medicine.
- •Active peptic ulceration as Baclofen stimulates gastric acid secretion.
- •Porphyria.
- •Participants who are currently engaged in illicit drug use or alcohol abuse, according to DSM-5 criteria.
- •Participants who have previously participated in a clinical trial with arbaclofen (other than our AIMS-2-CT1).
- •Women who are breastfeeding
研究组 & 干预措施
arbaclofen
Experimental
干预措施: Arbaclofen (Drug)
placebo
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Change in power in the low frequency bands (theta/alpha) (between visits 1 and 2).
时间窗: baseline to day 7
To predict long term response to arbaclofen based on a single dose response during the placebo-controlled randomized single dose double blind stage.
次要结局
- Latency of N170 change (between visits 1 and 2).(baseline to day 7)
- Change of Autism Impact Measure (AIM total (Kanne et al., 2014b, Silkey et al., 2023) and subscales. • Change in the Social Responsiveness Scale (SRS total and subscales; Constantino & Gruber, 2012a).(from baseline to end of treatment)
- Change in power in the higher frequency bands (gamma/beta); connectivity in the theta and alpha bands; (between visits 1 and 2).(baseline to day 7)
研究者
研究点 (5)
Loading locations...
相似试验
招募中
3 期
A Follow-Up Shiftability Study of Arbaclofen with an Open-Label Extension for the study of Biomarkers for Treatment for Social Function in Children and Adolescents with Autism Spectrum Disordersautism spectrum disorder2023-508407-20-00Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon105
已完成
Bioequivalence
布洛芬缓释胶囊人体生物等效性研究用于缓解轻至中度疼痛如头痛、关节痛、偏头痛、牙痛、肌肉痛、神经痛、痛经。也用于普通感冒或流行性感冒引起的发热。CTR20241970河北山姆士药业有限公司
已完成
Unknown
一项在健康成年受试者中评价艾诺韦林与氟康唑药代动力学相互作用的临床研究治疗 HIV 药物CTR20230685江苏艾迪药业有限公司
Unknown
1 期
索氟布韦片在中国健康受试者中的药代动力学研究慢性丙型肝炎ChiCTR1800017298自筹48
Unknown
1 期
健康受试者氟康唑对艾瑞昔布片药代动力学的影响研究（单中心、单臂、开放、自身对照）人体药代动力学与药物药物相互作用ChiCTR-OIB-15007606江苏恒瑞医药股份有限公司12